We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Verseon (DI) | LSE:VSN | London | Ordinary Share | COM USD0.001 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 74.00 | 70.00 | 78.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMVSN
RNS Number : 9904X
Verseon Corporation
16 August 2018
For immediate release 16 August 2018
Verseon Corporation
("Verseon" or the "Company")
Change of Adviser
Fremont, Calif.- Verseon (AIM:VSN), a technology-based pharmaceutical company employing a computer-driven platform to develop a diverse drug pipeline, today announces the appointment of Arden Partners plc as nominated adviser and joint broker to the Company with immediate effect.
- Ends -
For further information, please contact:
Hot Features
Premium
Verseon Corporation www.verseon.com
Sebastian Wykeham +1 (510) 225 9000
Arden Partners (NOMAD and Joint Broker)
+44 (0) 20 7614
Ruari McGirr / Maria Gomez De Olea 5900
Cantor Fitzgerald Europe (Joint Broker)
+44 (0) 20 7894
Marc Milmo / Phil Davies 7000
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers)
+44 (0) 20 7466
Henry Harrison-Topham / Jamie Hooper 5000
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that pairs a proprietary, computational drug discovery platform with a comprehensive in-house chemistry and biology workflow to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
APPGUGDILDBBGIL
(END) Dow Jones Newswires
August 16, 2018 02:01 ET (06:01 GMT)
1 Year Verseon Chart |
1 Month Verseon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
